abstract |
The present invention comprises methods and pharmacological compositions comprising an antigen and a nucleoside adjuvant that modulates the balance between type 1 and type 2 responses in lymphocytes, wherein the nucleoside is not an 8-substituted guanine nucleoside, and Relates to the composition. In a preferred embodiment of the present invention, the adjuvant of the present invention stimulates a type 1 response and consequently increases the T-cell response, while the adjuvant of the present invention also stimulates a type 2 response, so that B -It can also increase the cellular response. Preferred adjuvants of the invention may further comprise a synergistic amount of Cp-G dinucleotide and / or Cp-G containing oligonucleotide. |